Gaboxadol

Gaboxadol

Chemical structure of Gaboxadol

Gaboxadol is a pharmacological compound that was initially developed as a potential treatment for insomnia and other sleep disorders. It is a derivative of muscimol, a psychoactive compound found in certain mushrooms. Gaboxadol acts as a selective agonist at the GABA_A receptor, specifically targeting the extrasynaptic receptors that mediate tonic inhibition in the central nervous system.

Mechanism of Action

Gaboxadol exerts its effects by binding to the GABA_A receptor, which is a major inhibitory neurotransmitter receptor in the brain. Unlike traditional benzodiazepines, which enhance the effect of GABA at synaptic receptors, Gaboxadol selectively activates extrasynaptic GABA_A receptors. This action results in a sustained inhibitory effect, which is thought to contribute to its sedative and hypnotic properties.

Development and Clinical Trials

Gaboxadol was originally developed by Lundbeck and later co-developed with Merck & Co. for the treatment of insomnia. During clinical trials, Gaboxadol showed promise in improving sleep onset and maintenance. However, its development was discontinued in 2007 due to concerns about its safety profile and the emergence of adverse effects in some patients.

Potential Uses

Although Gaboxadol was not approved for the treatment of insomnia, research into its mechanism of action has continued. There is interest in its potential use for other neurological conditions, such as epilepsy and anxiety disorders, due to its unique action on the GABAergic system.

Chemical Properties

Gaboxadol is chemically known as 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol. Its structure is characterized by a bicyclic ring system that includes an isoxazole ring fused to a pyridine ring. This structure is crucial for its activity at the GABA_A receptor.

Related Pages

• GABA receptor
• Insomnia
• Benzodiazepine
• Neurotransmitter